Cue Biopharma (CUE) stock: insider trades, news & valuation
Net sellingShare price and insider trades
Cue Biopharma insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $98K and 3 sold $2.0M of CUE stock on the open market.
Get emailed when insiders cluster-buy stocks like CUE
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
CUE insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $2.0M | 11 |
| Q2 2026 | — | 0 | — | 0 |
| Q1 2026 | — | 0 | — | 0 |
| Q4 2025 | $100K | 5 | — | 0 |
Valuation, profit and volume
Summary
Over the past 12 months, 1 Cue Biopharma, Inc. insider reported open-market purchases totaling $98K, while 3 insiders reported sales totaling $2.0M. 0 of 11 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Aug 17SEC | Sumita RayGeneral Counsel | Sell | 6,442118,549 held (−5%) | $30.35 | $196K | -8.9% | — |
| Aug 17SEC | Michael Vincent MeluzioVp, Prin. Accounting Officer | Sell | 4,10648,964 held (−8%) | $30.35 | $125K | -8.9% | — |
| Aug 17SEC | Sumita RayGeneral Counsel | Sell | 2,383124,991 held (−2%) | $29.37 | $70K | -5.8% | — |
| Aug 17SEC | Michael Vincent MeluzioVp, Prin. Accounting Officer | Sell | 1,51953,070 held (−3%) | $29.37 | $45K | -5.8% | — |
| Aug 17SEC | Sumita RayGeneral Counsel | Sell | 4118,545 held (−0%) | $31.13 | $125 | -11.1% | — |
| Aug 17SEC | Michael Vincent MeluzioVp, Prin. Accounting Officer | Sell | 348,961 held (−0%) | $31.13 | $93 | -11.1% | — |
| Aug 14SEC | Shao-lee LinCEO | Sell | 34,225730,028 held (−4%) | $26.99 | $924K | +2.5% | — |
| Aug 14SEC | Shao-lee LinCEO | Sell | 10,460705,995 held (−1%) | $29.48 | $308K | -6.2% | — |
| Aug 14SEC | Shao-lee LinCEO | Sell | 5,775724,253 held (−1%) | $27.75 | $160K | -0.3% | — |
| Aug 14SEC | Shao-lee LinCEO | Sell | 5,423718,830 held (−1%) | $27.19 | $147K | +1.7% | — |
| Aug 14SEC | Shao-lee LinCEO | Sell | 2,375716,455 held (−0%) | $28.11 | $67K | -1.6% | — |
| Jan 2SEC | Pasha SarrafDirector | Buy | 86,947168,324 held (+107%) | $0.32 | $28K | +8543.8% | — |
| Jan 2SEC | Pasha SarrafDirector | Buy | 78,116246,440 held (+46%) | $0.31 | $24K | +8822.6% | — |
| Jan 2SEC | Pasha SarrafDirector | Buy | 77,417323,857 held (+31%) | $0.30 | $23K | +9120.0% | — |
| Jan 2SEC | Pasha SarrafDirector | Buy | 77,14881,377 held (+1824%) | $0.30 | $23K | +9120.0% | — |
| Jan 2SEC | Pasha SarrafDirector | Buy | 4,229new position | $0.31 | $1K | +8822.6% | — |
Insiders at Cue Biopharma, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Shao-lee LinCEO | — | $1.6M | Aug 14, 2026 | — |
| Pasha SarrafDirector | $100K | — | Jan 2, 2026 | — |
| Sumita RayGeneral Counsel | — | $266K | Aug 17, 2026 | — |
| Michael Vincent MeluzioVp, Prin. Accounting Officer | — | $169K | Aug 17, 2026 | — |
CUE stock: common questions
Are Cue Biopharma, Inc. insiders buying CUE stock?
In the past 12 months, 1 insiders reported open-market purchases of CUE worth $98K. The latest was Director Pasha Sarraf bought $28K of CUE at $0.32 — largest purchase by this insider in our records; raises the stake by 107%.
Are Cue Biopharma, Inc. insiders selling CUE stock?
3 insiders reported sales worth $2.0M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is CUE's 52-week range?
Over the past year CUE has traded between $5.31 and $37.84. It last closed at $27.66 on Oct 9, 2026.